BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bindal P, Gray JE, Boyle TA, Florou V, Puri S. Biomarkers of therapeutic response with immune checkpoint inhibitors. Ann Transl Med 2021;9:1040. [PMID: 34277840 DOI: 10.21037/atm-20-6396] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Vathiotis IA, Trontzas I, Gavrielatou N, Gomatou G, Syrigos NK, Kotteas EA. Immune Checkpoint Blockade in Hormone Receptor-Positive Breast Cancer: Resistance Mechanisms and Future Perspectives. Clin Breast Cancer 2022:S1526-8209(22)00140-9. [PMID: 35906130 DOI: 10.1016/j.clbc.2022.06.004] [Reference Citation Analysis]
2 Kang Z, Li W, Yu YH, Che M, Yang ML, Len JJ, Wu YR, Yang JF. Identification of Immune-Related Genes Associated With Bladder Cancer Based on Immunological Characteristics and Their Correlation With the Prognosis. Front Genet 2021;12:763590. [PMID: 34899848 DOI: 10.3389/fgene.2021.763590] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]